Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place

被引：2
|
作者：
Meerveld-Eggink, A. [1 ]
Graafland, N. [2 ]
Wilgenhof, S. [1 ]
Van Thienen, J. V. [1 ]
Grant, M. [3 ]
Szabados, B. E. [4 ]
Abu-Ghanem, Y. [5 ]
Boleti, E. [6 ]
Blank, C. U. [1 ]
Haanen, J. B. A. G. [1 ]
Powles, T. B. [7 ]
Bex, A. [8 ]
机构：
[1] Antoni van Leeuwenhoek Hosp NKI AVL, Dept Med Oncol, Netherlands Canc Inst, Amsterdam, Netherlands
[2] Netherlands Canc Inst, Urol, Amsterdam, Netherlands
[3] Queen Mary Univ London, Med Oncol, Barts Canc Inst, London, England
[4] Barts Canc Inst, Dept Med Oncol, London, England
[5] Royal Free London NHS Fdn Trust, Urol, London, England
[6] Royal Free Hosp, Acad Oncol Dept, Sch Med, London, England
[7] St Bartholomews Hosp, Oncol, London, England
[8] Antoni van Leeuwenhoek Hosp NKI AVL, Netherlands Canc Inst, Surg Oncol Urol Dept, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.809
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
737P
引用
收藏
页码：S575 / S575
页数：1
相关论文
共 50 条
  • [1] Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place.
    Meerveld-Eggink, Aafke
    Graafland, Niels
    Wilgenhof, Sofie
    Van Thienen, Johannes V.
    Grant, Michael
    Szabados, Bernadett
    Abu-Ghanem, Yasmin
    Boleti, Ekaterini
    Blank, Christian U.
    Haanen, John B. A. G.
    Powles, Thomas
    Bex, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Outcome of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place
    Jurascheck, L.
    Van de Putte, Fransen E.
    Van den Brink, L.
    Van der Mijn, J. C.
    Wilgenhof, S.
    Van Thienen, J. V.
    Haanen, J. B. A. G.
    Boleti, E.
    Powles, T.
    Zondervan, P. J.
    Graafland, N. M.
    Bex, A.
    EUROPEAN UROLOGY, 2024, 85 : S1859 - S1860
  • [3] PHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M.
    Rini, B. I.
    McDermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M.
    Sharma, P.
    Kollmannsberger, C. K.
    Heng, D.
    Shen, Y.
    Kurland, J.
    Spratlin, J.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2014, 25
  • [4] Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Ernstoff, Marc S.
    Rini, Brian I.
    McDermott, David F.
    Razak, Albiruni R. A.
    Pal, Sumanta Kumar
    Voss, Martin Henner
    Sharma, Padmanee
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Spratlin, Jennifer L.
    Shen, Yun
    Kurland, John F.
    Gagnier, Paul
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).
    Leong, Sally
    Ali, Sana
    Zengin, Zeynep Busra
    Meza, Luis A.
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Govindarajan, Ameish
    Castro, Daniela V.
    Li, Xiaochen
    Kim, Tane
    Melamed, Sam
    Pal, Sumanta Monty
    Chehrazi-Raffle, Alex
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [6] Phase I study of nivolumab in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M. S.
    Rini, B.
    Mcdermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M. H.
    Sharma, P.
    Kollmannsberger, C.
    Heng, D. Y. C.
    Spratlin, J.
    Shen, Y.
    Kurland, J. F.
    Gagnier, P.
    Amin, A.
    BJU INTERNATIONAL, 2014, 114 : 8 - 8
  • [7] Impact of treatment line on outcomes with salvage ipilimumab plus nivolumab in metastatic renal cell carcinoma (mRCC).
    Kotecha, Ritesh
    Lee, Chung-Han
    Knezevic, Andrea
    Shah, Neil J.
    Carlo, Maria Isabel
    Feldman, Darren R.
    Patil, Sujata
    Motzer, Robert J.
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renalcell carcinoma (mRCC) treated with ipilimumab/nivolumab (I plus N).
    Zhang, Tian
    Wu, Yuan
    Agarwal, Anika
    Starr, Mark D.
    Reyes-Martinez, Marco
    Anand, Monika
    Runyambo, Daniella
    Harrison, Michael Roger
    Armstrong, Andrew J.
    George, Daniel J.
    Nixon, Andrew B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [9] Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
    Numakura, Kazuyuki
    Sekine, Yuya
    Hatakeyama, Shingo
    Muto, Yumina
    Sobu, Ryuta
    Kobayashi, Mizuki
    Sasagawa, Hajime
    Kashima, Soki
    Yamamto, Ryohei
    Nara, Taketoshi
    Akashi, Hideo
    Tabata, Ryuji
    Sato, Satoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    CANCER MEDICINE, 2023, 12 (16): : 16837 - 16845
  • [10] Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab
    Desai, Kunal
    Brown, Landon Carter
    Wei, Wei
    Allman, Kimberly D.
    Martin, Allison
    Wood, Laura S.
    Gupta, Shilpa
    Gilligan, Timothy D.
    Garcia, Jorge A.
    Kao, Chester
    Kinsey, Emily Noelle
    Healy, Patrick
    Kephart, Julie
    Harrison, Michael Roger
    Ramalingam, Sundhar
    Armstrong, Andrew J.
    George, Daniel J.
    Rini, Brian I.
    Zhang, Tian
    Ornstein, Moshe Chaim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345